Dr. Rondeep Singh Brar, MD

Dr. Brar practices at Stanford Hospital at 300 Pasteur Drive in Stanford, California, part of Stanford University.

Dr. Brar's NPI, 1932389277, was assigned on November 3, 2007. Dr. Brar graduated from David Geffen School of Medicine at UCLA in 2007. Dr. Brar holds California license A105055.

Dr. Brar's primary practice is Stanford Hospital at 300 Pasteur Drive, at 300 Pasteur Drive, Stanford, CA 94305 in Santa Clara County. The practice phone is (650) 723-4000.

Dr. Brar's primary practice is Stanford Hospital at 300 Pasteur Drive in Stanford, California, part of Stanford University. Dr. Brar is also affiliated with Dignity Health - Dominican Hospital. The medical group on file is Stanford Health Care. Dmand AI also links Dr. Brar to 1 more hospital and 1 medical group, each named with a free account. Dr. Brar's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Brar practices, 3 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Brar's primary specialty in the NPI Registry, under taxonomy code 207RH0000X. The record also lists hematology. Dr. Brar is board certified in hematology by the American Board of Internal Medicine. Dr. Brar is licensed in California.

Dmand AI lists breast cancer, chronic anemia, chronic leukemia, deep vein thrombosis (DVT), lung cancer, lymphoma, multiple myeloma and prostate cancer among the conditions Dr. Brar treats.

CMS data shows 389 Medicare services from Dr. Brar across 5 procedure codes in 2024, for 136 Medicare patients. Medicare paid $45,385 for them.

CMS counts 136 Medicare patients who saw Dr. Brar in 2024. The largest group is 75 to 84, with 56 patients. 75% of them have high blood pressure, and 72% have high cholesterol. 26% are also on Medicaid. Their average risk score is 2.62, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Brar's median patient age at 64, with 53% women.

In 2024, Dr. Brar wrote 34 Medicare Part D claims. 53% of them were for generic drugs. CMS names the drug for 11 of them, across 1 drug with 11 or more claims each, at $6,588 in total drug cost. In 2021, CMS named 29 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 89 out of 100 for Dr. Brar for performance year 2024, reported as part of a group. Dr. Brar accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Brar as offering telehealth.

Dmand AI links 7 papers to Dr. Brar, published from 2009 to 2022. 2019 was the busiest year, with 2. Dr. Brar's most frequent co-authors are David Joseph Iberri, MD, Wilson Mawutor Alobuia, MD and James B. Bussel, MD.

Dmand AI links Dr. Brar to 2 clinical trials. Conditions studied include Leukemia, Megakaryoblastic, Acute, Leukemia, Myeloid, Acute and Leukemia, Erythroblastic, Acute.

CMS Open Payments shows 30 general payments to Dr. Brar from 5 drug and device companies from 2018 to 2025. Consulting fees make up the largest share, 82% of the total. Alexion Pharmaceuticals, Inc. paid the most, $28,751.

Dmand AI lists 1 award for Dr. Brar, most recently CMS Stage 1 EHR in 2013.

Dr. Brar graduated from David Geffen School of Medicine at UCLA in 2007.

Dr. Brar is in network with 10 carriers, including Aetna, Excellus BlueCross BlueShield and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 7. Check the plan with the practice before a visit.